Millipore Sigma Vibrant Logo

475940 MT4-MMP, Catalytic Domain, His•Tag®, Human, Recombinant, E. coli

475940
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited Availability
Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information
      Description
      Overview

      This product has been discontinued.





      Recombinant, human pro-MT4-MMP fused at the C-terminus to a His•Tag® sequence, expressed in E. coli as a periplasmic protein and activated to yield the active catalyic domain. MT4-MMP catalytic domain can be used to study the biological function of MT4-MMP and its interactions with other matrix metalloproteases.
      Note: 1 mU = 1 milliunit.
      Catalogue Number475940
      Brand Family Calbiochem®
      SynonymsMMP-17 Catalytic Domain
      References
      ReferencesGilles, C., et al. 1997. Lab Invest. 76, 651.
      Puente, X.S., et al. 1996. Cancer Res. 56, 944.
      Takino, T., et al. 1995. J. Biol. Chem. 270, 23013.
      Knight, C.G., et al. 1992. FEBS Lett. 296, 263.
      Product Information
      Unit of DefinitionOne unit is defined as the amount of enzyme that will hydrolyze 1.0 µmol MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂ (<a href ="/Products/ProductDisplay.asp→catNO=03-32-5032">Cat. No. 03-32-5032</a>) per min at 37°C, pH 7.5.
      FormLiquid
      FormulationIn 150 mM NaCl, 50 mM Tris-HCl, 5 mM CaCl₂, 0.1% TRITON® X-100 Detergent, pH 7.5.
      Applications
      Biological Information
      Purity≥80% by SDS-PAGE
      Specific Activity≥8 mU/mg protein
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      475940 0

      Documentation

      References

      Reference overview
      Gilles, C., et al. 1997. Lab Invest. 76, 651.
      Puente, X.S., et al. 1996. Cancer Res. 56, 944.
      Takino, T., et al. 1995. J. Biol. Chem. 270, 23013.
      Knight, C.G., et al. 1992. FEBS Lett. 296, 263.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-September-2007 RFH
      SynonymsMMP-17 Catalytic Domain
      DescriptionRecombinant, human pro-MT4-MMP fused at the C-terminus to a His•Tag® sequence, expressed in E. coli as a periplasmic protein and activated to yield the active catalyic domain. The catalytic domain is comprised of amino acid residues Q to L of mature human MT4-MMP, with a C-terminal linked polyhistidine-tag. MT4-MMP catalytic domain can be used to study the biological function of MT4-MMP and its interactions with other matrix metalloproteinases.
      FormLiquid
      FormulationIn 150 mM NaCl, 50 mM Tris-HCl, 5 mM CaCl₂, 0.1% TRITON® X-100 Detergent, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      Recommended reaction conditions
      Activity Assay
      Reagent Preparation and Required Equipment Peptide Hydrolysis Buffer: 150 mM NaCl, 50 mM Tris-HCl, 5 mM CaCl2, 0.025 % Brij® 35 detergent, pH 7.5. Store at 4°C; stable for several weeks. Peptide Substrate Stock: 100 µM Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg (Cat. No. 05-32-5032) in 20% DMSO. Store at -20°C. Peptide Standard: 10 µM (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-NH2 (Mca-Pro-Leu) (Cat. No. 05-32-5033) in 20% DMSO. Store at -20°C. Fluorimeter: Excitation wavelength: ~328 nm; emission wavelength: ~393 nm
      Protocol Note: This protocol is provided only as a guide; assay conditions should be optimized for individual experiments.
      The protocol is based on the following reference: Knight, C.G., et al. 1992. FEBS Lett. 296, 263.
      1. Calibrate the fluorimeter using the Peptide Standard (Mca-Pro-Leu) at a concentration that corresponds to 2–10% hydrolysis of the Peptide Substrate. 2. Kinetic Dilute the Peptide Substrate Stock to 8 µM in Peptide Hydrolysis Buffer and equilibrate to 37°C. 3. Add 2–4 µl MT4-MMP and record the increase in fluorescence at desired intervals from 2–12 min. 4. Calculate activity in units per ml enzyme using the following equation: Activity (U/ml) = cMca-Pro-Leu/FMca-Pro-Leu x ΔFMca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg/venzyme x Vtotal cMca-Pro-Leu: Concentration of Mca-Pro-Leu used for calibration of the fluorimeter (µmol/ml) FMca-Pro-Leu: Fluorescence of Mca-Pro-Leu at the concentration cMca-Pro-Leu used for fluorimeter calibration ΔFMca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg: Change in fluorescence during peptide hydrolysis per min V: Volume of peptide hydrolysis reaction (2.5 ml) v: Volume of added enzyme (2–4 µl)
      Purity≥80% by SDS-PAGE
      Specific activity≥8 mU/mg protein
      Unit definitionOne unit is defined as the amount of enzyme that will hydrolyze 1.0 µmol MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂ (Cat. No. 03-32-5032) per min at 37°C, pH 7.5.
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesGilles, C., et al. 1997. Lab Invest. 76, 651.
      Puente, X.S., et al. 1996. Cancer Res. 56, 944.
      Takino, T., et al. 1995. J. Biol. Chem. 270, 23013.
      Knight, C.G., et al. 1992. FEBS Lett. 296, 263.